Category Archives: Uncategorized

This study assessed the risk of developing nonarteritic anterior ischemic optic neuropathy (NAION) after cataract surgery. Source: AAO

• Posted on: Sep 27 2019
• By: Saratoga Opthalmology
• Leave a response

This week, Roche unveils their new AI algorithm for predicting diabetic retinopathy progression, the NEI and Prova Education develops curriculum to educate physicians about diabetic eye diseases and a theatre actor with Stargardt disease makes his TV debut. Source: AAO

• Posted on: Sep 26 2019
• By: Saratoga Opthalmology
• Leave a response

This secondary analysis of data from 2 clinical trials explores whether the type of anti-VEGF agent and baseline characteristics influence fellow eye conversion to neovascular AMD. Source: AAO

• Posted on: Sep 26 2019
• By: Saratoga Opthalmology
• Leave a response

This NEI-funded trial compared 2 commonly used, steroid-sparing, immunosuppressive drugs as a first-line treatment for noninfectious uveitis. Source: AAO

• Posted on: Sep 25 2019
• By: Saratoga Opthalmology
• Leave a response

Investigators evaluated the outcomes of transepithelial phototherapeutic keratectomy with corneal collagen crosslinking in patients with pellucid marginal degeneration. Source: AAO

• Posted on: Sep 24 2019
• By: Saratoga Opthalmology
• Leave a response

This study assessed the clinical efficacy and safety of primary selective laser trabeculoplasty (SLT) for open-angle glaucoma (OAG) and ocular hypertension. Source: AAO

• Posted on: Sep 23 2019
• By: Saratoga Opthalmology
• Leave a response

This report details the current approach for the management of syphilitic uveitis. Source: AAO

• Posted on: Sep 20 2019
• By: Saratoga Opthalmology
• Leave a response

This week, a baby beams at his father after surgery for congenital cataracts, an ultraprecise cannula delivers drugs into retinal veins and the FDA clears Canon’s automated OCT device. Source: AAO

• Posted on: Sep 20 2019
• By: Saratoga Opthalmology
• Leave a response

Investigators assessed the incidence of ocular myasthenia gravis (MG) and identified risk factors for transformation to generalized MG. Source: AAO

• Posted on: Sep 19 2019
• By: Saratoga Opthalmology
• Leave a response

A novel monotherapy may reduce the risk of relapse for patients with neuromyelitis optica spectrum disorder (NMOSD), according to data presented by Genentech at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Source: AAO

• Posted on: Sep 18 2019
• By: Saratoga Opthalmology
• Leave a response